Proliferative retinopathy in a patient with mutation in the CLCN2 gene
European Journal of Ophthalmology · 2025
DOI: 10.1177/11206721251316612 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Ophthalmology, 2025. Verfasst von Waseem Nasser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel. Hauptthemen laut MEDLINE: Chloride Channels, Mutation, Vitreoretinopathy, Proliferative. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Purpose
CLCN2 is a gene that encodes the voltage-gated chloride channel protein 2 in the human brain and eyes. While mutations in this gene have been associated with leukoencephalopathy as well as ocular manifestations including optic neuropathy and choroidopathy, here we report for the first time a case of severe proliferative retinopathy in a patient with CLCN2 mutation. Observations A 12-year-old girl with Familial Mediterranean Fever (FMF) was referred due to blurred vision in both eyes. Ophthalmoscopic examination revealed mild vitreous hemorrhage, large neovascularization at the disc (NVD), extensive neovascularization along the arcades (i.e., NVE; neovascularization elsewhere), retinal arteriolar narrowing, silver sheathing of the veins and preretinal hemorrhages. Fluorescein angiography (FA) demonstrated prominent leakage from multiple large NVEs. A thorough and multidisciplinary evaluation ruled out metabolic, thrombotic, infectious, inflammatory, or autoimmune etiologies. Notably, however, brain magnetic resonance imaging (MRI) revealed leukodystrophy yet poorly correlated with her clinical manifestation. Strikingly, whole exome sequencing uncovered a homozygous mutation in the CLCN2 gene. She was treated with intravitreal injections of the anti-vascular endothelial growth factor (VEGF) antibody Bevacizumab and laser pan-retinal photocoagulation (PRP) with partial response.
Conclusions
This case suggests that CLCN2 mutation may possess a key role in an aggressive form of proliferative retinopathy with partial response to anti-VEGF therapy. We hypothesize that the potential underlying mechanism involves astrocyte dysfunction and retinal blood barrier disruption. Noteworthy, a comprehensive approach is unequivocally significant in evaluating such cases of proliferative retinopathy with unclear etiology to establish a diagnosis and management strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel.
- The Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
- Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa, Israel.
- Department of Pediatrics and Pediatric Rheumatology Unit, Rambam Health Care Campus, Ruth Children's Hospital, Haifa, Israel.
- Genetics Institute, Rambam Medical Center, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Metabolic Clinic and Pediatric Department B, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
ORCID-Profile: Waseem Nasser
Zitieren
APA
Nasser, W., Pizem, H., Butbul Aviel, Y., Hershkovitz, T., Tal, G., Zayit-Soudry, S., & Naaman, E. (2025). Proliferative retinopathy in a patient with mutation in the CLCN2 gene. European Journal of Ophthalmology. https://doi.org/10.1177/11206721251316612
Vancouver
Nasser W, Pizem H, Butbul Aviel Y, Hershkovitz T, Tal G, Zayit-Soudry S, et al. Proliferative retinopathy in a patient with mutation in the CLCN2 gene. European Journal of Ophthalmology. 2025. doi:10.1177/11206721251316612
BibTeX
@article{Nasser2025,
author = {Nasser, Waseem and Pizem, Hadas and Butbul Aviel, Yonatan and Hershkovitz, Tova and Tal, Galit and Zayit-Soudry, Shiri and Naaman, Efrat},
title = {Proliferative retinopathy in a patient with mutation in the CLCN2 gene},
journal = {European Journal of Ophthalmology},
year = {2025},
doi = {10.1177/11206721251316612}
}
EUVIMED